Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Download Data

Alpha Tau Medical Ltd Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Alpha Tau Medical Ltd Tangible Asset Value Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The tangible asset value ratio measures the proportion of tangible assets to total assets. It is calculated by dividing the tangible assets by the total assets. This ratio indicates the significance of tangible assets, such as property, plant, and equipment, in the company's total asset structure. A higher ratio suggests a higher proportion of tangible assets relative to total assets.

Alpha Tau Medical Ltd Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.88, a 190.60% change year over year.
Alpha Tau Medical Ltd Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.98, a -22.14% change year over year.
Alpha Tau Medical Ltd Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.80.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends